Reference health
COVID-19 and Disease-Modifying Anti-rheumatic Drugs
52/52 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
11 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 52 checked references that resolve
resolves10.1002/acr2.11148
Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the <scp>COVID</scp>‐19 Pandemic
resolves10.1080/1744666X.2020.1792778
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19
resolves10.1136/annrheumdis-2020-217871
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
resolves10.1053/j.gastro.2020.05.032
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
resolves10.1136/gutjnl-2020-322539
Effect of IBD medications on COVID-19 outcomes: results from an international registry
resolves10.1016/j.jaci.2020.10.007
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
resolves10.1001/jama.2020.17022
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
resolves10.1001/jama.2020.22240
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19
resolves10.1056/NEJMoa2019014
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
resolves10.1001/jamainternmed.2020.6615
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
resolves10.1001/jamainternmed.2020.6820
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
resolves10.1001/jamanetworkopen.2020.13136
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019
resolves10.1101/2020.08.06.20169573
Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial
resolves10.1056/NEJMc2009567
Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York
resolves10.1136/annrheumdis-2020-217424
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
resolves10.1136/annrheumdis-2020-217600
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
resolves10.1136/annrheumdis-2020-217615
What is the true incidence of COVID-19 in patients with rheumatic diseases?
resolves10.1016/j.autrev.2020.102575
SARS-CoV-2 infection among patients with systemic autoimmune diseases
resolves10.1016/j.semarthrit.2020.05.001
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
resolves10.1136/annrheumdis-2020-217627
Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China
resolves10.1136/annrheumdis-2020-217888
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot‘
resolves10.1016/j.cell.2020.08.025
Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
resolves10.1016/j.cell.2020.11.025
Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
resolves10.1002/art.41437
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 2
resolves10.1016/j.healun.2020.03.012
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
resolves10.1136/annrheumdis-2020-217460
Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19
resolves10.1001/jama.2020.17023
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
resolves10.1093/cid/ciaa478
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
resolves10.1002/art.41469
Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐Analysis
resolves10.1056/NEJMoa2016638
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
resolves10.1001/jamainternmed.2020.6319
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
resolves10.2139/ssrn.3615997
Hydroxychloroquine Alone or in Combination with Cobicistat-Boosted Darunavir for Treatment of Mild COVID-19: A Cluster-Randomized Clinical Trial
resolves10.1001/jamainternmed.2020.6252
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
resolves10.1016/S0140-6736(20)30304-4
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
resolves10.1080/1744666X.2021.1847084
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation
resolves10.1016/S2665-9913(20)30120-X
The immunology of COVID-19: is immune modulation an option for treatment?
resolves10.1097/CCM.0000000000001402
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome
resolves10.1002/art.41422
Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
resolves10.1016/j.ijid.2020.11.149
Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study
resolves10.1186/s13054-020-03364-w
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
resolves10.1016/j.medj.2020.11.005
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
resolves10.1136/annrheumdis-2020-219174
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
resolves10.1136/annrheumdis-2020-219787
Response to: ‘Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’’ by Kawada
The 11 references without a DOI — listed, not checked
no DOI — not checkedCoronavirus disease 2019 dashboard: World Health Organization; [2-3-21]. Available from: https://covid19.who.int/.
no DOI — not checked•• Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;Advance online publication. In this follow-up study from the Global Rheumatology Alliance physician-reported reigstry, rheumatic disease patients on rituximab, sulfasalazine, or certain immunosuppressants (including azathioprine, cyclophosphamide, cyclosporine, mycophenolate, or tacrolimus) had higher odds of death than comparators on methotrexate monotherapy.
no DOI — not checked•• Horby PW, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19: preliminary report. N Engl J Med. 2020;Advance online publication. This large RCT of dexamethasone vs. usual care was the first study to report that glucocorticoids lowered the risk of mortality in patients hospitalized with COVID-19.
no DOI — not checked•• Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report. medRxiv. 2021;Advance online publication. This RCT of tocilizumab or sarilumab vs. usual care in patients with COVID-19 requiring intensive care showed a greater number of organ support-free days and greater survival in the arm receiving IL-6 receptor inhibitor therapy.
no DOI — not checked•• Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020;Advance online publication. This RCT of baricitinib vs. placebo on background remdesivir therapy in hospitalized COVID-19 showed shorter time to recovery in the baricitinib-treated arm.
no DOI — not checked• Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;Advance online publication. This RCT of anakinra vs. usual care in patients hospitalized with COVID-19 showed no effect on clinical status or a composite outcome of intubation or death.
no DOI — not checked• Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv. 2021;Advance online publication. This RCT of colchicine vs. placebo in non-hospitalized COVID-19 showed a trend towards reduced risk of hospitalization or death in the colchicine-treated arm, although the trial was stopped early due to logistical reasons, limiting interpretability.
no DOI — not checkedConticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis. 2021;80(0):1–2.
no DOI — not checkedTang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:1–11.
no DOI — not checkedMitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild COVID-19: a randomized-controlled trial. Clin Infect Dis. 2020; Advance online publication.
no DOI — not checkedWHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med. 2020; Advance Online Publication.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s11926-021-00998-9"><img src="https://citestamp.com/citestamped/10.1007/s11926-021-00998-9/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s11926-021-00998-9)